Add BrightSurf on Google Email

Search results for “Oncology”

1,000+ results for "Oncology"

International panel led by RCSI Professor classifies immunotherapy side effects for the first time

An international panel of experts has developed standardized definitions for immunotherapy side effects, providing a shared vocabulary for clinicians to standardize clinical practice guidelines. This will help support clinicians in offering the best treatment to patients and enable research into biomarkers predicting adverse effects.

SourceRCSI·JournalJournal for ImmunoTherapy of Cancer·DateApr 4, 2023

New study in JNCCN identifies approach for improving end-of-life conversations for people with cancer

A new study published in JNCCN identifies a targeted approach to improve end-of-life conversations for people with cancer. Researchers found that specially trained oncology infusion room nurses can increase the rate of advance care planning, leading to more supported decision-making.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·TypeRandomized controlled/clinical trial·DateApr 4, 2023

NRG Oncology combined trial long-term results indicate that pathologic complete response is prognostic of outcomes for soft tissue sarcoma patients

The NRG Oncology combined trial results indicate that pathologic complete response (pCR) is associated with improved survival outcomes for patients with localized soft tissue sarcoma. pCR can be used as a prognostic factor for clinical outcomes in future STS research, with patients achieving higher overall and disease-free survival rates.

SourceNRG Oncology·JournalJAMA Oncology·DateMar 31, 2023

National Comprehensive Cancer Network updates annual conference with new in-person venue, hybrid format, expert-led sessions, highlighted research perspectives, and small-group conversations

The NCCN Annual Conference will debut a new hybrid format featuring in-person events at a new venue, allowing for hallway conversations and networking opportunities. The conference will also showcase more than 100 abstract poster presentations on various oncology-related categories.

Immunotherapy costs drive increase in Medicare spending for outpatient cancer care at the end of life

A recent study found that immunotherapy costs accounted for 84% of the net increase in Medicare spending on outpatient cancer care at the end of life. Payments for radiation oncology decreased by 2%, while palliative care spending rose, reflecting a shift towards hypofractionated radiation treatments.

SourceAmerican Society for Radiation Oncology·JournalInternational Journal of Radiation Oncology*Biology*Physics·DateFeb 27, 2023

Strata Oncology announces publication of study validating clinical utility of pan-tumor predictive biomarker for checkpoint inhibitor immunotherapy benefit

The study validated the clinical utility of Strata Oncology's proprietary pan-solid tumor predictive biomarker, Immunotherapy Response Score (IRS), which predicts response to checkpoint inhibitor therapy. IRS captures tumor biology and microenvironment by combining tumor mutation burden with quantitative expression of PD-L1, PD-1, ADAM...

SourceStrata Oncology·JournalCommunications Medicine·TypeData/statistical analysis·DateFeb 7, 2023

Study finds large gap in breast cancer treatment recommendations for patients aged 70 vs 69

Researchers analyzed over 500,000 patient records and found that patients diagnosed at age 70 were nearly twice as likely to be passed over for post-surgical radiation therapy. This significant gap in treatment recommendations suggests that cognitive heuristics play a major role in physician decision-making.

SourceAmerican Society for Radiation Oncology·JournalInternational Journal of Radiation Oncology*Biology*Physics·DateJan 31, 2023

Concentration of surgery has improved operations for childhood cancer

Researchers at the Princess Máxima Center found that concentrating surgery for children with neuroblastoma resulted in shorter operation times and reduced blood loss. The study also showed a decrease in side effects, although further research is needed to confirm improved survival rates.

SourcePrincess Máxima Center for Pediatric Oncology·JournalEuropean Journal of Surgical Oncology·TypeData/statistical analysis·DateDec 19, 2022

Largest study of its kind reveals adjuvant chemotherapy improves overall survival for pancreatic cancer patients

A nationwide retrospective study showed that adjuvant chemotherapy after neo-adjuvant chemotherapy and surgery significantly improved overall survival in patients with pancreatic adenocarcinoma, regardless of lymph node status or resection margins. The study included nearly 900 patients and was published in JAMA Oncology.

THE LANCET ONCOLOGY: Experts warn of a European cancer epidemic in the next decade if weaknesses in cancer health systems and cancer research are not urgently addressed

A new report by the European Groundshot Commission highlights current and future challenges in cancer research across Europe. The authors estimate that approximately one million cancer diagnoses were missed during the COVID-19 pandemic, and the war in Ukraine poses a significant threat to clinical trials and workforce gaps.

SourceThe Lancet·JournalThe Lancet Oncology·TypeSystematic review·DateNov 15, 2022

Shorter course of radiation therapy yields comparable results for patients with non-metastatic soft tissue sarcoma

Patients with non-metastatic soft tissue sarcoma can safely receive hypofractionated treatment over three weeks instead of five, achieving similar tumor control and no increased risk of wound complications. The study found comparable rates of major wound complications between the two treatment courses.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalThe Lancet Oncology·DateNov 4, 2022

Lower prostate cancer screening rates associated with subsequent increase in advanced cancers

A large-scale analysis of VA medical centers found that facilities with lower yearly PSA screening rates had higher rates of metastatic prostate cancer in subsequent years. The study supports the benefits of prostate cancer screening in reducing metastatic prostate cancer risk, particularly for high-risk groups like Black patients.

SourceAmerican Society for Radiation Oncology·JournalJAMA Oncology·DateOct 24, 2022

NRG Oncology trial NRG-HN004 shows addition of durvalumab to radiation does not improve outcomes over cetuximab for head & neck squamous cell carcinoma patients with a contraindication to cisplatin, highlights need for further research

The NRG-HN004 trial found that radiotherapy with durvalumab did not improve progression-free survival or overall survival compared to cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma who have a contraindication to cisplatin. The study highlighted the need for further research in this population.

New recommendations address the use of integrative therapies for pain management in cancer populations

The new SIO-ASCO guideline recommends the use of acupuncture, massage therapy, and other integrative therapies for managing breast cancer-related joint pain, general cancer pain, and chemotherapy-induced peripheral neuropathy. The guidelines also acknowledge areas that need further research to support their recommendations.

SourceThe Reis Group·JournalJournal of Clinical Oncology·DateSep 19, 2022

There’s a better way to detect high-risk medications in older adults with cancer according to new study in JNCCN

A new scale called the Geriatric Oncology-Potentially Inappropriate Medications (GO-PIMs) Scale was found to be more effective at predicting frailty than conventional methods. The scale identifies high-risk medications linked to falls and fatigue, allowing oncology teams to deprescribe them and improve patients' overall health.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateAug 10, 2022

Critical oncology trial data remains hidden

A multi-national study found that over half of clinical trials leading to FDA-approved anticancer medicines are not available for independent scrutiny. The lack of transparency hinders the use of data for further research into the safety and efficacy of medicines.

SourceFlinders University·JournalJAMA Oncology·TypeData/statistical analysis·DateJul 28, 2022

Improving serious illness communication for patients with advanced cancer

A quality improvement project at Dartmouth Cancer Center increased serious illness conversations between patients and providers from 0% to 70%, reflecting the importance of early discussions on prognosis and treatment options. The project's success was attributed to standardized work, an engaged interdisciplinary team, and system-level...

SourceDartmouth Health·JournalJCO Oncology Practice·TypeRandomized controlled/clinical trial·DateJul 20, 2022

PSA-based endpoints should not be used as surrogate endpoints for overall survival in men with recurrent prostate cancer at this time

A study published in the Journal of Clinical Oncology found that biochemical failure is not a reliable surrogate endpoint for overall survival in patients with recurrent prostate cancer. The researchers recommend considering metastasis-free survival (MFS) as the best surrogate endpoint for overall survival in this population.

SourceNRG Oncology·JournalJournal of Clinical Oncology·DateJun 29, 2022

New drug combination lengthened survival for some with lung cancer

A new drug combination of ramucirumab and pembrolizumab significantly extended overall survival in advanced non-small cell lung cancer patients who had progressed on prior immunotherapy. The study found a 31% reduction in risk of death compared to standard therapy, with median overall survival times of 14.5 months.

SourceSWOG Cancer Research Network·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateJun 3, 2022

The Society for Integrative Oncology names JICM their official journal

The Society for Integrative Oncology has partnered with the Journal of Integrative and Complementary Medicine (JICM) to advance evidence-based integrative healthcare. This partnership benefits SIO members by offering discounted Open Access publishing fees, while also providing worldwide exposure for research in integrative oncology.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalJournal of Integrative and Complementary Medicine·TypeNews article·DateMay 23, 2022

Researchers identify reliable measures of racial inequities in quality of oncology care

A study of over 4,800 medical oncology practices found that Black patients had higher rates of chemotherapy-related emergency department visits and hospitalizations compared to white patients. The researchers developed reliable measures to assess these inequities, with potential for identifying high- and low-equity practices.

SourceBrigham and Women's Hospital·JournalHealth Affairs·TypeObservational study·DateApr 7, 2022

HRR mutational status prognostic of survival outcomes in biomarker analysis of NRG oncology trial for women with recurrent platinum-sensitive ovarian cancer

The study found that homologous recombination repair mutant type (HRRmt) was prognostic of progression-free survival and predictive for olaparib activity in women with recurrent platinum-sensitive ovarian cancer. Patients with BRCA mutations showed clinically significant activity when treated with experimental drugs.

Adjuvant compared to early salvage therapy post prostatectomy in men with PN1 prostate cancer and decreased risk of mortality

Researchers found that adjuvant radiation therapy compared to early salvage therapy reduced mortality risk in men with pN1 prostate cancer. The study, published in the Journal of Clinical Oncology, showed a 8% decrease in mortality for each additional positive pelvic lymph node found at surgery.

SourceBrigham and Women's Hospital·JournalJournal of Clinical Oncology·TypeObservational study·DateMar 15, 2022

COVID vaccination is also recommended for people with cancer

A comprehensive review of over 60 studies confirms that COVID vaccination is around 80% effective in protecting people with cancer against SARS-CoV-2 infection. The mRNA vaccines were found to be the most effective, and multiple vaccinations are recommended for better protection.

SourceLeibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute -·JournalNature Reviews Clinical Oncology·TypeLiterature review·DateMar 14, 2022

One third of children with a kidney tumor has hereditary predisposition

A new study by the Princess Máxima Center for Pediatric Oncology has found that one third of children with a Wilms' tumor, the most common form of childhood kidney cancer, have a hereditary predisposition. This discovery has led to the implementation of extensive genetic testing for all children with this disease in the Netherlands.

SourcePrincess Máxima Center for Pediatric Oncology·JournalJournal of Clinical Oncology·TypeObservational study·DateMar 1, 2022

Oncology dietitians rarely ask cancer patients about food insecurity, study finds

A study by researchers at the University of Illinois found that oncology dietitians rarely ask cancer patients about food insecurity, despite awareness that many experience it. The dietitians' estimates of prevalence varied widely, and most did not use validated tools to screen for food insecurity.

SourceUniversity of Illinois at Urbana-Champaign, News Bureau·JournalJournal of the Academy of Nutrition and Dietetics·TypeSurvey·DateFeb 11, 2022

New tool in cancer battle

A new dietary tool can quickly and accurately assess micronutrient levels in oncology patients, helping to find better nutritional solutions for cancer treatment. Tested on 112 patients, the 21-item food frequency questionnaire can identify suboptimal micronutrient intakes in just 10 minutes.

SourceFlinders University·JournalNutrients·TypeExperimental study·DateFeb 10, 2022

Prioritized supportive care needs of patients and caregivers during active cancer treatment

A new study from Regenstrief Institute identifies divergent priorities among cancer patients and their caregivers during active treatment, with patients focusing on physical issues like pain and caregivers prioritizing social support. The research emphasizes the need for enhanced whole-family approaches to supportive oncology care deli...

SourceRegenstrief Institute·JournalJCO Oncology Practice·DateFeb 1, 2022

Trastuzumab with chemoradiation and surgery does not improve outcomes for esophageal cancer patients, trial highlights future research opportunities

The NRG-RTOG 1010 clinical trial found that adding trastuzumab to chemoradiation and surgery did not improve disease-free survival for HER2-positive esophageal adenocarcinoma patients. Despite this, the study highlights future research opportunities to explore combining trastuzumab with other HER2-targeting agents.

SourceNRG Oncology·JournalThe Lancet Oncology·DateJan 21, 2022

International meta-analysis quantifies impact of three prostate cancer therapy intensification strategies

A new meta-analysis of randomized clinical trials found that adding androgen deprivation therapy (ADT) to definitive radiotherapy prevents one cancer from metastasizing for every 10 to 15 men treated. Prolonging adjuvant ADT also showed significant benefits, while neoadjuvant ADT was not effective beyond two months.

SourceUniversity of California - Los Angeles Health Sciences·JournalThe Lancet Oncology·TypeMeta-analysis·DateJan 19, 2022